Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | EVP AND GC | April 18, 2018 | April 20, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date April 18, 2018 · Filed April 20, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.98 · Expires 2028-04-17 | Direct | 28,125 |
Reported balance
After 2018-04-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-04-18 · Grant · Acquired 28,125 · Balance 28,125 F1: 25% of the shares subject to the Stock Option vest and become exercisable on April 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the Stock Option vest and become exercisable on April 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 18, 2018 Filed Apr 20, 2018 22:37 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 28,125 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001415889-18-000659 · form4-04202018_030410.xml · derivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,125 Underlying: Common Stock · 28,125 shares Expires 2028-04-17 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on April 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 22:56 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 36,558 | $32.39 | $1,184,055.13 |
DisclosureSEC source: 0001415889-18-000158 · form4-01312018_020102.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,734 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017 and amended in November 2017. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.37 to $32.45 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| January 10, 2018 Filed Jan 11, 2018 21:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 50,179 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001415889-18-000043 · form4-01112018_010112.xml · derivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,179 shares Expires 2022-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 23, 2013. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| January 10, 2018 Filed Jan 11, 2018 21:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 50,179 | $2.18 | $109,390.22 |
DisclosureSEC source: 0001415889-18-000043 · form4-01112018_010112.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 23:24 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 74,321 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001415889-18-000014 · form4-01042018_030117.xml · derivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,321 shares Expires 2022-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 23, 2013. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 23:24 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 74,321 | $30.14 | $2,240,138.99 |
DisclosureSEC source: 0001415889-18-000014 · form4-01042018_030117.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,113 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017 and amended in November 2017. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.335 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 23:24 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 74,321 | $2.18 | $162,019.78 |
DisclosureSEC source: 0001415889-18-000014 · form4-01042018_030117.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 457 shares acquired on November 15, 2017 by Mr. Baity under the ACADIA Pharmaceuticals Employee Stock Purchase Plan. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 22:20 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · derivative · entry 11 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2018-10-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 50% of the shares subject to the Stock Option vested and became exercisable on October 20, 2010. The remaining shares vested and became exercisable thereafter in 24 equal monthly installments. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 22:20 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · derivative · entry 10 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2021-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 22:20 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · derivative · entry 9 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,500 Underlying: Common Stock · 1,000 shares Expires 2022-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 23, 2013. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 22:20 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 37,500 | $40.91 | $1,534,042.50 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · nonDerivative · entry 6 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,656 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017. F2 · shares: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.605 to $41.065 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 22:20 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 20,000 | $2.00 | $40,000.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · nonDerivative · entry 5 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 22:20 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 7,500 | $1.62 | $12,150.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · nonDerivative · entry 4 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 22:20 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,000 | $2.18 | $2,180.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · nonDerivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 22:20 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · derivative · entry 8 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,500 Underlying: Common Stock · 4,500 shares Expires 2022-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 23, 2013. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 22:20 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · derivative · entry 7 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 6,500 shares Expires 2021-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 22:20 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 4,500 | $2.18 | $9,810.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 22:20 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,500 | $1.62 | $10,530.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 22:15 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 46,875 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001415889-17-001472 · form4-09082017_030909.xml · derivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,875 Underlying: Common Stock · 46,875 shares Expires 2027-09-06 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on September 7, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 21:15 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 16,507 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-17-001447 · form4-09012017_020900.xml · derivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 16,507 shares Expires 2021-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 21:15 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 26,507 | $34.87 | $924,314.99 |
DisclosureSEC source: 0001415889-17-001447 · form4-09012017_020900.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,656 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.87 to $34.88 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 21:15 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 16,507 | $1.62 | $26,741.34 |
DisclosureSEC source: 0001415889-17-001447 · form4-09012017_020900.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 21:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 13,400 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-17-001378 · form4-08112017_020820.xml · derivative · entry 5 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,507 Underlying: Common Stock · 13,400 shares Expires 2021-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 21:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 922 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001415889-17-001378 · form4-08112017_020820.xml · derivative · entry 4 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 922 shares Expires 2020-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 12, 2011. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 21:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 14,322 | $34.88 | $499,534.17 |
DisclosureSEC source: 0001415889-17-001378 · form4-08112017_020820.xml · nonDerivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,656 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.87 to $34.91 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 21:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 13,400 | $1.62 | $21,708.00 |
DisclosureSEC source: 0001415889-17-001378 · form4-08112017_020820.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 21:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 922 | $1.55 | $1,429.10 |
DisclosureSEC source: 0001415889-17-001378 · form4-08112017_020820.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2017 Filed Aug 8, 2017 22:29 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-17-001348 · form4-08082017_030851.xml · derivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,907 Underlying: Common Stock · 6,500 shares Expires 2021-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| August 04, 2017 Filed Aug 8, 2017 22:29 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,500 | $1.62 | $10,530.00 |
DisclosureSEC source: 0001415889-17-001348 · form4-08082017_030851.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 21:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 28,097 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-17-001265 · form4-07212017_020745.xml · derivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,097 shares Expires 2021-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 21:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 38,097 | $30.00 | $1,142,910.00 |
DisclosureSEC source: 0001415889-17-001265 · form4-07212017_020745.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,156 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 21:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 28,097 | $1.62 | $45,517.14 |
DisclosureSEC source: 0001415889-17-001265 · form4-07212017_020745.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 21:35 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 1,903 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-17-001046 · form4-06262017_020620.xml · derivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,097 Underlying: Common Stock · 1,903 shares Expires 2021-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 21:35 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 1,903 | $30.00 | $57,090.76 |
DisclosureSEC source: 0001415889-17-001046 · form4-06262017_020620.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,156 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.01 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 21:35 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,903 | $1.62 | $3,082.86 |
DisclosureSEC source: 0001415889-17-001046 · form4-06262017_020620.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:42 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 14,093 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-17-000785 · form4-05172017_020549.xml · derivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,000 Underlying: Common Stock · 14,093 shares Expires 2021-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:42 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 14,093 | $1.62 | $22,830.66 |
DisclosureSEC source: 0001415889-17-000785 · form4-05172017_020549.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2017 Filed Mar 11, 2017 01:36 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 46,875 | $0.00 Strike: $36.54 | $0.00 |
DisclosureSEC source: 0001415889-17-000406 · form4-03102017_050329.xml · derivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,875 Underlying: Common Stock · 46,875 shares Expires 2027-03-07 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on March 8, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 6,365 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001415889-17-000281 · form4-02162017_040242.xml · derivative · entry 6 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,365 shares Expires 2018-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on October 22, 2009. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 3,224 | $0.00 Strike: $8.32 | $0.00 |
DisclosureSEC source: 0001415889-17-000281 · form4-02162017_040242.xml · derivative · entry 5 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,224 shares Expires 2018-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 7, 2009. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 16,776 | $0.00 Strike: $8.32 | $0.00 |
DisclosureSEC source: 0001415889-17-000281 · form4-02162017_040242.xml · derivative · entry 4 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,776 shares Expires 2018-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 7, 2009. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 26,365 | $39.66 | $1,045,517.26 |
DisclosureSEC source: 0001415889-17-000281 · form4-02162017_040242.xml · nonDerivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,063 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015, as amended in May 2016. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $39.71 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,365 | $1.64 | $10,438.60 |
DisclosureSEC source: 0001415889-17-000281 · form4-02162017_040242.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 20,000 | $8.32 | $166,400.00 |
DisclosureSEC source: 0001415889-17-000281 · form4-02162017_040242.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 23:50 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 21,078 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001415889-17-000182 · form4-02032017_030250.xml · derivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,078 shares Expires 2020-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 12, 2011. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 23:50 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 31,078 | $35.15 | $1,092,382.38 |
DisclosureSEC source: 0001415889-17-000182 · form4-02032017_030250.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,063 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2016. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.10 to $35.315 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 23:50 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 21,078 | $1.55 | $32,670.90 |
DisclosureSEC source: 0001415889-17-000182 · form4-02032017_030250.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2016 Filed Dec 29, 2016 22:09 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-16-007636 · form4-12292016_021237.xml · derivative · entry 5 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,093 Underlying: Common Stock · 5,500 shares Expires 2021-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| December 28, 2016 Filed Dec 29, 2016 22:09 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 5,500 | $1.62 | $8,910.00 |
DisclosureSEC source: 0001415889-16-007636 · form4-12292016_021237.xml · nonDerivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2016 Filed Dec 29, 2016 22:09 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 9,800 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001415889-16-007636 · form4-12292016_021237.xml · derivative · entry 4 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,078 Underlying: Common Stock · 9,800 shares Expires 2020-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 12, 2011. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.